ストックスクリーナーアプリを入手
0.299
3.22%
0.01
前日終値:
$0.289
開ける：
$0.29
24時間の取引高:
224.49K
Relative Volume:
0.29
時価総額：
$28.35M
収益：
$1.22M
当期純損益:
$-14.15M
株価収益率:
-1.15
EPS:
-0.26
ネットキャッシュフロー:
$-6.55M
1週間 パフォーマンス:
+6.01%
1か月 パフォーマンス:
+0.13%
6か月 パフォーマンス:
-5.99%
1年 パフォーマンス:
-13.54%
1日の値動き範囲:
$0.2894
$0.30
1週間の範囲:
$0.276
$0.30
52週間の値動き範囲:
$0.2525
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
IGC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2983 | 27.47M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.82 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
798.82 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.23 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.92 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.39 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
IGC Pharma Inc (IGC) 最新ニュース
Can IGC Pharma Inc. (IGS1) stock sustain institutional flowsStock Price Forecasts & Analyze Your Portfolio Risk in Seconds - bollywoodhelpline.com
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability - Finviz
IGC Pharma (IGC) Aligns Fiscal Year with Calendar Year - GuruFocus
IGC Pharma Announces Registered Direct Equity Offering Financing - TipRanks
IGC Pharma Signs Subscription Agreement With Certain Investors - TradingView — Track All Markets
How IGC Pharma Inc. (IGS1) stock expands through international markets2026 world cup usa national team round of 32 midfield engines high defensive line tactical prediction preview - Улправда
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial - BioSpace
IGC Pharma (IGC) Secures Funding Through Share Sale - GuruFocus
Small biotech secures cash to keep its Alzheimer's trial moving - Stock Titan
IGC Pharma Adjusts Fiscal Year-End to December 31 - TipRanks
IGC Pharma increases authorized shares to 600 million - MSN
Operating cash flow per share of IGC Pharma, Inc. – SWB:IGS1 - TradingView — Track All Markets
IGC Pharma Inc. (IGC) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Would You Still Hold IGC Pharma Stock If It Fell Another 30%? - Trefis
IGC Pharma (FRA:IGS1) EV-to-OCF : -4.65 (As of Dec. 21, 2025) - GuruFocus
How IGC Pharma Inc. stock responds to policy changesWeekly Trend Summary & Long-Term Capital Growth Strategies - Улправда
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum - Big News Network.com
Will IGC Pharma Inc. stock outperform benchmarksInflation Watch & Verified Swing Trading Watchlists - Улправда
IGC Pharma Secures U.S. Patent for Innovative Stuttering Treatme - GuruFocus
What makes IGC Pharma Inc. stock appealing to growth investors2025 Trading Volume Trends & Accurate Buy Signal Notifications - DonanımHaber
How IGC Pharma Inc. stock benefits from strong dollarWeekly Trade Report & High Return Trade Opportunity Guides - DonanımHaber
Can IGC Pharma Inc. stock deliver strong Q4 earningsWeekly Investment Summary & Technical Buy Zone Confirmation - DonanımHaber
Why IGC Pharma Inc. stock remains stableJuly 2025 Selloffs & Low Risk Growth Stock Ideas - DonanımHaber
Aug Analyst Calls: How IGC Pharma Inc. (IGS1) stock expands through international markets2025 Pullback Review & Long-Term Growth Stock Strategies - Улправда
IGC Pharma Inc - Reuters
IGC Pharma comments on potential reclassification of cannabis - MSN
IGC Pharma Increases Authorized Shares to 600 Million - The Globe and Mail
IGC Pharma Positions as a Singular Beneficiary of Emerging Feder - GuruFocus
IGC Pharma (IGC) Advances in FDA-regulated Cannabinoid Drug Deve - GuruFocus
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cann - pharmiweb.com
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines - Weatherford Democrat
IGC Pharma Inc IGC’s stock price falss traction on Thursday - uspostnews.com
It is Poised to be a Bull Market for IGC Pharma Inc (IGC) - setenews.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Digital Journal
IGC Pharma : Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.” - marketscreener.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We - pharmiweb.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the - Big News Network.com
IGC Pharma Achieves 65% Enrollment In Phase 2 CALMA Trial For Alzheimer's Agitation - Nasdaq
Ascendiant Capital Markets Issues Positive Forecast for IGC Pharma (NYSEMKT:IGC) Stock Price - Defense World
Ascendiant Capital Maintains IGC Pharma (IGC) Buy Recommendation - Nasdaq
IGC Pharma (IGC): Ascendiant Capital Raises Price Target to $4.7 - GuruFocus
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 C - GuruFocus
IGC Achieves Significant Enrollment Progress in Phase 2 Alzheimer's Trial - GuruFocus
IGC Pharma Inc (IGC) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):